| First Author | Zheng M | Year | 2020 |
| Journal | Cancer Immunol Immunother | Volume | 69 |
| Issue | 11 | Pages | 2345-2355 |
| PubMed ID | 32514619 | Mgi Jnum | J:298320 |
| Mgi Id | MGI:6472200 | Doi | 10.1007/s00262-020-02627-3 |
| Citation | Zheng M, et al. (2020) ADRB3 expression in tumor cells is a poor prognostic factor and promotes proliferation in non-small cell lung carcinoma. Cancer Immunol Immunother 69(11):2345-2355 |
| abstractText | The cross-talk between cancer cells and monocyte-derived alveolar macrophages (Mo-AMs) promotes non-small cell lung carcinoma (NSCLC) progression. In this study, we report that both cancer cells and Mo-AMs robustly express beta 3-adrenergic receptor (ADRB3) in NSCLC. ADRB3 supports lung cancer cells proliferation and promotes chronic inflammation. Genetic and pharmacologic inhibition of ADRB3 reverses tumor growth and inflammation in mouse. Furthermore, we demonstrate that M5D1, a novel anti-ADRB3 monoclonal antibody, inhibits human lung cancer cells proliferation and inflammation via affecting the intracellular mTOR pathway and activating p53. In NSCLC patients, we confirmed that upregulation of ADRB3 expression correlates with tumor progression and poor prognosis. Altogether, these results shed light on the role of ADRB3 in NSCLC and suggest that M5D1 could become powerful antitumor weapons. |
